A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chiu Nan-Chang | - |
dc.contributor.author | Clifford, Robert | - |
dc.contributor.author | Huang Li-Min | - |
dc.contributor.author | Huang Yhu-Chering | - |
dc.contributor.author | Jo, Dae Sun | - |
dc.contributor.author | Kim, Chun Soo | - |
dc.contributor.author | Kim, Hwang Min | - |
dc.contributor.author | Kim, Kwang-Nam | - |
dc.contributor.author | Kim, Kyung-Hyo | - |
dc.contributor.author | Kim, Yun-Kyung | - |
dc.contributor.author | Klein, Nicola P. | - |
dc.contributor.author | Ma, Sang-Hyuk | - |
dc.contributor.author | Peltier, Christopher | - |
dc.contributor.author | Senders, Shelly | - |
dc.contributor.author | Shepard, Julie | - |
dc.contributor.author | Wu, Tsung Zu | - |
dc.contributor.author | Yeh, Shu Jen | - |
dc.contributor.author | Zissman, Edward | - |
dc.contributor.author | Gillard, Paul | - |
dc.contributor.author | Povey, Michael | - |
dc.contributor.author | Abu-Elyazeed, Remon | - |
dc.contributor.author | Henry, Ouzama | - |
dc.date.accessioned | 2021-09-01T16:15:44Z | - |
dc.date.available | 2021-09-01T16:15:44Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-04-03 | - |
dc.identifier.issn | 2164-5515 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/66048 | - |
dc.description.abstract | In many countries, a second dose of a combined measles, mumps, and rubella (MMR) vaccine is recommended at 4-6 years of age - similarly to the booster of diphtheria, tetanus, acellular pertussis, and inactivated polio vaccine (DTaP-IPV) and the second dose of varicella vaccine (VV). Vaccine co-administration is generally encouraged if no interferences exist among the vaccines. This phase IIIa, randomized, controlled trial (NCT01621802) evaluated the immunogenicity and safety of MMR-RIT (Priorix, GSK) when given as a second dose with or without co-administration of DTaP-IPV and VV, using MMR II (M-M-R II, Merck & Co Inc.) as comparator. Antibody geometric mean concentrations or titers (GMCs/GMTs) and response rates to the components of all the administered vaccines were assessed. Solicited, unsolicited, and serious adverse events were recorded. Four thousand eleven children aged 4-6 years were enrolled. MMR-RIT elicited immune responses that were not inferior to those of MMR II in terms of GMCs and seroresponse rates when administered alone or when co-administered with DTaP-IPV and VV. The immune responses to the co-administered vaccines in MMR-RIT recipients were non-inferior to those in MMR II recipients. MMR-RIT and MMR II demonstrated similar reactogenicity profiles; the most frequent solicited adverse events across vaccine groups and sub-cohorts were local pain and fever. In conclusion, the immunogenicity and safety profiles of MMR-RIT administered with or without DTaP-IPV and VV were similar to those of MMR II. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS INC | - |
dc.subject | PREVENTION | - |
dc.title | A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yun-Kyung | - |
dc.identifier.doi | 10.1080/21645515.2018.1554971 | - |
dc.identifier.wosid | 000467847400006 | - |
dc.identifier.bibliographicCitation | HUMAN VACCINES & IMMUNOTHERAPEUTICS, v.15, no.4, pp.786 - 799 | - |
dc.relation.isPartOf | HUMAN VACCINES & IMMUNOTHERAPEUTICS | - |
dc.citation.title | HUMAN VACCINES & IMMUNOTHERAPEUTICS | - |
dc.citation.volume | 15 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 786 | - |
dc.citation.endPage | 799 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordAuthor | Measles-mumps-rubella vaccine | - |
dc.subject.keywordAuthor | DTaP-IPV | - |
dc.subject.keywordAuthor | varicella vaccine | - |
dc.subject.keywordAuthor | immunogenicity | - |
dc.subject.keywordAuthor | safety | - |
dc.subject.keywordAuthor | co-administration | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.